PFS Analysis
| Univariate | Multivariate | ||||||
| Parameter | Group | HR | 95% CI | P | HR | 95% CI | P |
| Ki-67 | Q1: <2% | 1 | 0.002 | 1 | 0.044 | ||
| Q2: 2%–5% | 1.165 | 0.898–1.513 | 1.171 | 0.880–1.557 | |||
| Q3: 5%–10% | 1.466 | 1.111–1.934 | 1.419 | 1.041–1.935 | |||
| Q4: >10% | 1.631 | 1.230–2.163 | 1.493 | 1.090–2.045 | |||
| Comorbidities | Diabetes | 1.373 | 0.989–1.907 | 0.058† | 1.706 | 1.117–2.605 | 0.013 |
| Prior treatment | Chemotherapy | 1.362 | 1.123–1.652 | 0.002† | 1.375 | 1.039–1.820 | 0.026 |
| Interferon-α | 1.487 | 1.046–2.114 | 0.027 | 2.054 | 1.211–3.485 | 0.008 | |
| CgA (μg/L) | Q1: <112 | 1 | <0.001 | 1 | <0.001 | ||
| Q2: 112–333 | 1.189 | 0.932–1.517 | 1.267 | 0.922–1.741 | |||
| Q3: 336–1,168 | 1.580 | 1.241–2.011 | 1.469 | 1.084–1.992 | |||
| Q4: >1,168 | 2.148 | 1.679–2.747 | 2.039 | 1.488–2.794 | |||
HR > 1 indicates greater risk for disease progression compared with reference value (HR = 1).